[ad_1]
Biotech and biopharmaceutical companies, including CNS Rare Disease Management, have begun researching solutions for the treatment of brain tumors by zebrafish.
The brainwashing zebrafish model applied to this screening is a model completed in 2017 by Professor Chul-hee Kim, a professor at the National University of Chungnam, and by Wojung Bio, a national project.
This model can evaluate effective substances that can inhibit seizures by drug efficacy in zebrafish, which are inherently seizure-prone.
Therefore, the use of this model has the advantage of mbad screening for drug efficacy in the treatment of cerebral infarction, which effectively reduces the time and cost of developing new drugs.
"We hope that the zebrafish-based epilepsy drug screening technology will become a new platform for drug development screening more effective in the future of drug development," the statement said. Dr. Woo Jeong, Head of Bio-Relations Sector. "We will be able to explore drugs faster and cheaper than animal models, and the value of zebrafish will be even higher in Korea."
Woong Jeong Bio is developing new breeding programs based on precision medicine and infectious disease management activities, and is also promoting the establishment of a biopharmaceutical development center in Dongtan.
[ad_2]
Source link
